Article
How Targeted Therapy Disrupts the Treatment Paradigm for Acquired TTP: The Risks, Benefits, and Unknowns.
Blood
(2019)
Abstract
Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targeted therapies. Immunomodulatory strategies target anti-ADAMTS13 antibodies: rituximab is effective in inducing responses in refractory/relapsed TTP and increasing relapse-free survival; caplacizumab targets the von Willebrand factor-platelet interaction to hasten platelet count recovery and reduce mortality and TTP-related ischemic events. Bortezomib and recombinant ADAMTS13 are under investigation. This review examines how targeted therapies are disrupting current treatment paradigms to improve outcomes of iTTP.
Disciplines
Publication Date
August 1, 2019
Citation Information
Camila Masias and Additional authors and institutional affiliations. "How Targeted Therapy Disrupts the Treatment Paradigm for Acquired TTP: The Risks, Benefits, and Unknowns." Blood (2019) Available at: http://works.bepress.com/camila-masiascastanon/27/